Inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C (rs11706052) and 12-month evolution of the graft function in renal transplant recipients on mycophenolate-based immunosuppression

Abstract

Abstract Variant allele at the inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T > C has been associated with increased enzyme activity and reduced susceptibility to mycophenolic acid (MPA) in vitro. It has been suggested associated with an increased risk of acute rejection in renal transplant recipients on MPA-based immunosuppression, but not unambiguously. We assessed one-year evolution of the estimated glomerular filtration rate (eGFR) in 52 variant carriers and 202 wild-type controls exposed to MPA. Adjusted for a range of demographic, pharmacogenetic, (co)morbidity, and treatment baseline and time-varying covariates, the eGFR slopes to day 28 (GMR = 1.01, 95%CI 0.93–1.09), and between days 28 and 365 (GMR = 1.01, 95%CI 0.99–1.02) were practically identical in variant carriers and wild-type controls. The estimates (95%CIs) remained within the limits of ±20% difference even after adjustment for a strong hypothetical effect of unmeasured confounders. Polymorphism IMPDH2 3757T > C does not affect the renal graft function over the 1st year after transplantation.